455 Mission Bay Boulevard South
Tel: 415-482-5300, Toll Free 855-482-NKTR (6587)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
320 articles with Nektar Therapeutics
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics
Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Howard Robin, is scheduled to present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019 at 9:00 a.m. Pacific Time.
Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
NKTR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR
Rosen Law Firm announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period").
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Nektar Therapeutics (NKTR) and December 31 Lead Plaintiff Deadline
Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and other defendants, related to alleged violations of federal securities laws.
11/19/2018Companies bolstered their leadership with additions to boards of directors and c-suite offices.
It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company named a Genentech veteran to helm its oncology programs.
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs
Dr. Lin will lead development strategy and study oversight of the company's immuno-oncology candidates and other oncology programs.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR
Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers.
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018.
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
Nektar Therapeutics announced that it has entered into an oncology clinical collaboration with Pfizer Inc. to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN).
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting
Nektar Therapeutics announced today that it will webcast an analyst and investor conference call with melanoma specialists and company management on Saturday, November 10, 2018 at 9:00 a.m. EST in Washington, D.C. during the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
11/2/2018Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!
Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018,
10/9/2018Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
Block & Leviton LLP is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers and directors violated federal securities laws.